目的:探討內鏡下氬離子凝固術(APC)聯合抑酸治療對Barrett食管的臨床療效。方法:選擇經內鏡及病理確診的Barrett食管患者40例,隨機分為兩組,治療組21例,對照組19例,治療組經內鏡下APC治療后聯合埃索美拉唑20mg 2次/日連續3月,對照組單用埃索美拉唑20mg 2次/日連續3月,分別于3月、6月、12月對兩組進行臨床癥狀積分和內鏡及病理隨訪。結果:兩組治療后3、6、12月臨床癥狀積分緩解無明顯差異性(Plt;0.05),但從內鏡、病理隨訪的有效率來看,治療組與對照組相比有顯著差異性(Plt;0.05)。結論:BE內鏡下APC聯合抑酸治療能有效逆轉Barrett上皮,是一種安全、有效的治療方法。
【摘要】 目的 探討膠囊內鏡對小腸疾病的診斷價值及順應性和安全性。 方法 分析2009年4月-2010年3月對35例疑有小腸疾病者行膠囊內鏡檢查的臨床資料。 結果 35例中發現小腸病變26例 （74.3%），包括血管畸形9例，間質瘤1例，息肉2例，小潰瘍 1例，非特異性炎癥 11例，寄生蟲2例，其中 4例患者同時存在兩種病變。所獲取的圖像質量良好。膠囊胃內運行平均時間為 62 min（5～460 min），小腸運行時間為 347 min（103～538 min），平均到達盲腸時間為384 min （120～540 min），平均記錄時間為547 min（299～605 min），平均獲取照片數為54 766張，膠囊排出體外時間平均為33 h（10～120 h）。受檢者順應性良好，無任何并發癥發生。 結論 膠囊內鏡是一種對小腸疾病具有較高的檢出能力；其安全性高、順應性好 。【Abstract】 Objective To investigate the diagnostic value of capsule endoscope for small intestine diseases, and to evaluate the compliance and security of capsule endoscopy. Methods The clinical data of 35 patients who underwent capsule endoscopy due to small bowel diseases between April 2009 and March 2010 were retrospectively analyzed. Results In the 35 patients, 26 (74.3%) had intestine diseases including vascular malformation in nine, interstitialoma in one, polyp in two, aphtha in one, non-specific inflammation in 11 and parasite in two; 4 patients had two lesions simultaneously. The quality of the obtained images was good. The average running time of the capsules in the stomach ranged from five to 460 minutes with an average time of 62 minutes. The running time of the capsules in the small intestine ranged from 103 to 538 minutes with an average of 347 minutes. The running time of the capsules arriving at the cecum ranged from 103 to 538 minutes with an average of 347 minutes. The time of the capsules egested out ranged from 10 to 120 hours with an average of 33 hours. The recording time ranged from 299 to 605 minuets with an average of 547 minutes. The mean acquired images were 54 766 pieces, The patients had good compliance, and none had any complications. Conclusion The capsule endoscopy had high security and good compliance. It has high detectivity in diagnosing small intestine diseases.
Objective To evaluate the efficacy and safety of high-dose dual therapy (HDDT) in the treatment of Helicobacter pylori (HP) infection. Methods The clinical data of patients with HP infection who were treated in Suining Central Hospital between June 2020 and August 2021 were retrospectively collected. They were divided into HDDT group and bismuth-containing quadruple therapy (BQT) group according to the treatment regimen. The efficacy and adverse reactions of the two treatment regimens were observed. Results A total of 520 patients were included. Among them, there were 284 cases in the HDDT group and 236 cases in the BQT group. By propensity score matching, 223 pairs of patients were successfully matched. The eradication rates of HDDT and BQT were 74.4% and 77.1%, respectively (χ2=0.440, P=0.507), and the incidence of adverse reactions were 9.9% and 16.6%, respectively (χ2=4.395, P=0.036). Conclusion The efficacy of HDDT and BQT in the treatment of HP infection is comparable, but the former has fewer adverse reactions.